Swiss-based start-up Biolytica has secured CHF 5.25 million in funding from the Maximon Longevity Co-Investment Fund. The company focuses on its Biolytica NEXUS platform, an AI-driven analytics platform that aggregates and analyzes health data from various sources. The platform provides solutions for healthcare professionals, insurance companies, and others to create personalized health journeys.
Since its incorporation in October 2021, Biolytica has launched the NEXUS platform to healthcare institutions and is already generating a six-figure turnover. The investment from Maximon will be used to establish Biolytica as a leading data platform for preventive healthcare and longevity, with plans to expand research and development efforts and collaborate with leading experts in personalized and preventive healthcare.
Biolytica's team comprises over 40 global experts in health data, analytics, software development, bioinformatics, and AI, along with clinical experts and 10 scientific and medical advisors. The company also offers B2C concierge health optimization and longevity programs supported by the Biolytica NEXUS platform.
Maximon's investment highlights the growing interest in longevity solutions backed by scientific research, as people around the world seek ways to extend their healthy lifespan.
